MEDTRONIC gets valve approval – TAVR System

DUBLIN – June 23, 2015 – Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the new recapturable, self-expanding CoreValveĀ® Evolut(TM) R System. The first-and-only recapturable and repositionable device available in the U.S., the Evolut R System is approved for transcatheter aortic valve replacement (TAVR) in severe aortic stenosis patients who are at high or extreme risk for surgery. Untreated, aortic valve stenosis can lead to serious heart problems including heart failure and even death.medicalglobal

Designed to treat patients with aortic stenosis, a condition where the aortic valve narrows thereby limiting blood flow from the aorta to the rest of the body, the CoreValve Evolut R System is built on the proven foundation and procedural success of the CoreValve System, which has been implanted in more than 75,000 patients in 60 countries. Continue reading

Why Linkedin Endorsement Feature Might Be Worthless

redwhitebusinessman-handshakeAm I good at helping companies calculate deferred compensation? I’m at least familiar with the concept, but I’m no expert.

Yet LinkedIn seems convinced that I know something about it, which is why the online professional networking service added it to my list of possible skills on my profile. Presumably that’s based on the fact that other people with similar job titles are good at deferred compensation. The scary part is, several people endorsed me for it. Continue reading